CEROW CERO THERAPEUTICS HLDGS INC revenue, earnings and financials
For the quarter ended June 30, 2026, CERO THERAPEUTICS HLDGS INC reported revenue of n/a, net income of −$1.03M and diluted EPS of −$0.70; for the fiscal year ended December 2025 revenue was n/a.
CEROW annual revenue and earnings
- Fiscal year ended Dec 2025: revenue n/a, gross profit n/a, operating income n/a, net income −$19.9M (margin n/a), EPS n/a
- Fiscal year ended Dec 2024: revenue n/a, gross profit n/a, operating income −$15.3M, net income −$7.73M (margin n/a), EPS −$18.15
- Fiscal year ended Dec 2023: revenue n/a, gross profit n/a, operating income −$7.68M, net income −$7.29M (margin n/a), EPS −$1248.64
- Fiscal year ended Dec 2022: revenue n/a, gross profit n/a, operating income −$2.91M, net income −$668K (margin n/a), EPS n/a
CEROW quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue n/a, net income −$1.03M, EPS −$0.70
- Quarter ended Mar 31, 2026: revenue n/a, net income −$5.89M, EPS −$0.20
- Quarter ended Dec 31, 2025 (from the annual report): revenue n/a, net income −$4.54M, EPS n/a
- Quarter ended Sep 30, 2025: revenue n/a, net income −$4.86M, EPS −$9.10
- Quarter ended Jun 30, 2025: revenue n/a, net income −$5.42M, EPS −$61.71
- Quarter ended Mar 31, 2025: revenue n/a, net income −$5.11M, EPS −$31.82
- Quarter ended Dec 31, 2024 (from the annual report): revenue n/a, net income $672K, EPS $466.63
- Quarter ended Sep 30, 2024: revenue n/a, net income −$4.23M, EPS −$170.22
- Quarter ended Jun 30, 2024: revenue n/a, net income −$2.45M, EPS −$302.32
- Quarter ended Mar 31, 2024: revenue n/a, net income −$1.73M, EPS −$12.24
- Quarter ended Dec 31, 2023 (from the annual report): revenue n/a, net income −$1.41M, EPS −$1247.99
- Quarter ended Sep 30, 2023: revenue n/a, net income −$1.35M, EPS −$0.15
- Quarter ended Jun 30, 2023: revenue n/a, net income −$2.09M, EPS −$0.23
- Quarter ended Mar 31, 2023: revenue n/a, net income −$2.44M, EPS −$0.27
- Quarter ended Dec 31, 2022 (from the annual report): revenue n/a, net income −$263K, EPS n/a
- Quarter ended Sep 30, 2022: revenue n/a, net income $84.5K, EPS n/a
- Quarter ended Jun 30, 2022: revenue n/a, net income −$112K, EPS n/a
- Quarter ended Mar 31, 2022: revenue n/a, net income −$378K, EPS n/a
- Quarter ended Sep 30, 2021: revenue n/a, net income $0, EPS $0.00
CEROW cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow −$16.1M, share buybacks n/a, dividends $10.37 per share
- Fiscal year ended Dec 2023: operating cash flow −$1.52M, share buybacks $33.5M
- Fiscal year ended Dec 2022: operating cash flow −$1.09M, share buybacks $139M
CEROW balance sheet
- Jun 30, 2026: cash $863K, total assets $1.90M, total liabilities $32.4M, shareholders' equity −$30.5M
- Mar 31, 2026: cash n/a, total assets $2.21M, total liabilities $11.5M, shareholders' equity −$9.26M
- Dec 31, 2025: cash n/a, total assets $3.64M, total liabilities $9.09M, shareholders' equity −$5.45M
- Sep 30, 2025: cash $1.90M, total assets $3.91M, total liabilities $8.45M, shareholders' equity −$4.54M
- Jun 30, 2025: cash $3.23M, total assets $6.20M, total liabilities $7.84M, shareholders' equity −$1.63M
- Mar 31, 2025: cash $5.10M, total assets $7.99M, total liabilities $8.32M, shareholders' equity −$329K
- Dec 31, 2024: cash n/a, total assets $6.21M, total liabilities $8.10M, shareholders' equity −$1.89M
- Sep 30, 2024: cash n/a, total assets $6.49M, total liabilities $10.2M, shareholders' equity −$3.70M
Is CEROW profitable?
No. CERO THERAPEUTICS HLDGS INC lost $16.3M over the last four quarters.
Does CEROW pay a dividend?
CERO THERAPEUTICS HLDGS INC paid $10.37 per share in dividends in the fiscal year ended December 2025.